The rise of Sildenafil initially fueled a boom for pharma, nevertheless recent changes present a uncertain picture for investors. Lower-cost competitors are eroding revenue, and ongoing patent challenges add further https://ammarutpv679205.free-blogz.com/88746208/the-blue-pill-and-pharma-a-volatile-bet